Palantir's 96% Revenue Surge Meets a Stalled Order Book and an Insider Sale

Palantir Technologies closed Tuesday's session lower as investors weighed a trio of developments that pull in different directions: an insider stock sale, a pair of new commercial partnerships, and quarterly numbers that were spectacular on the top line but raised questions about what comes next.

The stock slipped 1.3% on the day, according to one reading of the session, with another citing a 2.0% decline. The move came as Shyam Sankar filed a Form 144 with the US Securities and Exchange Commission disclosing a planned sale of 300,000 Palantir common shares. The mandatory notice lists the same Tuesday as the anticipated transaction date, though the filing does not confirm that the sale was completed.

A Growth Story With a Loose Thread

The third-quarter results, reported on November 2, set a high bar. Revenue reached $2.31 billion, up 96% from a year earlier. US commercial revenue climbed 148% to $984 million, overtaking US government revenue of $953 million for the first time.

Guidance for 2026 was lifted to 91% revenue growth, with the company projecting 143% growth in its US commercial segment. Yet the market's response to the quarter was tempered. Reports pointed to order backlogs that were largely flat versus the prior quarter, alongside tougher investor questions about whether AI-sector growth of this magnitude can be sustained.

That tension sits at the heart of the current investment debate. Impressive headline growth commands attention, but at these multiples the forward pipeline matters as much as the revenue already booked.

Two New Deployments to Watch

Against that backdrop, Palantir's commercial expansion offered concrete evidence of demand. Changshin announced a partnership with the company on November 5, with the two planning to deploy Foundry and the Artificial Intelligence Platform (AIP) across Changshin's shoe development and manufacturing operations. The tie-up spans both sides of the business.

AmeriLife also unveiled a company-wide partnership, bringing Foundry and AIP into its health and wealth distribution organizations. Crump Life Insurance Services is slated to lead the rollout.

For investors, these announcements matter most if the deployments deliver results in day-to-day operations. A signed partnership carries more weight once the platforms prove useful in the workflows they were designed for — and Changshin offers a specific, tangible test case.

The NHS Question

In the UK, reports suggest the government plans to extend Palantir's contract for the NHS Federated Data Platform. Ministers are said to have judged that replacing the company would be too disruptive, though the plan has drawn objections from lawmakers and clinical staff.

From a shareholder's perspective, that calculation cuts in Palantir's favor as long as the government holds to it. Deep integration into workflows makes a vendor hard to replace — and in this case, that difficulty appears to be part of the political reasoning itself. Still, a contract renewed because switching is awkward is a different proposition from one renewed on uncontested merit. The durability of the NHS relationship will ultimately be decided by its political staying power as much as its technical footprint.

What Would Justify the Optimism

Taken together, the quarter, the partnerships and the NHS deliberations paint a more nuanced picture of Palantir's customer base than any single item does. The company has compelling growth figures and fresh avenues for deepening client ties. What it needs now is for those new deployments and existing relationships to feed through into the order book. That is the yardstick by which confidence in the stock should be measured.